Bulls Eye Biotech, Bears Squeeze Hertz

Options traders are making bold bets this week. Three names dominate the flow with very different stories to tell.

Structure Therapeutics turned heads after Phase 2b obesity trial data landed in Nature Medicine. ORTEX flags a bullish options shift at the June 18 and July 17 expiries. Short interest sits at 10.6% of free float. That is moderate, not extreme. But availability is enormous at 2,897% of SI. Bears have no edge borrowing here. Bulls appear to be leaning into calls ahead of potential follow-on data catalysts.

Apollo Global Management reports earnings tomorrow. Options chains show active positioning across six expiries between June 12 and August. Short interest runs at 6.8% of free float. With availability at 232% of SI, shorts can enter freely. The short-dated activity into June 12 reads as earnings positioning rather than directional conviction.

Hertz sits in a different category entirely. Short interest is 39.9% of free float. Availability of shares to borrow is only 1.8% of SI. That is near-zero. New shorts face serious friction to enter. Options expiries run through late July. With the float almost fully locked up by existing shorts, any positive catalyst could force a rapid unwind. The setup closely resembles classic squeeze conditions.

NVDA shows the densest expiry calendar of any name. Contracts span from June 8 through September. Weekly expiry concentration remains in mid-June. That level of liquidity reflects ongoing trader interest near all-time highs, with no clear directional signal yet.

This is not financial advice.